<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01294358</url>
  </required_header>
  <id_info>
    <org_study_id>110099</org_study_id>
    <secondary_id>11-C-0099</secondary_id>
    <nct_id>NCT01294358</nct_id>
  </id_info>
  <brief_title>Regional Chemotherapy in Locally Advanced Pancreatic Cancer: RECLAP Trial</brief_title>
  <official_title>Regional Chemotherapy in Locally Advanced Pancreatic Cancer: RECLAP Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Background:

      - Pancreatic cancer is difficult to treat because by the time most cases are diagnosed, the
      tumors are too large to be removed surgically. Standard intravenous chemotherapy may shrink
      some of the tumor, but even with chemotherapy only about 25 percent of patients will live for
      1 year following diagnosis. Several preliminary studies have shown that it is safe to give
      chemotherapy directly into the pancreas in the area of the tumor, and that giving gemcitabine
      over a longer period increases the amount of drug that is available to the tumor. Researchers
      are interested in studying whether giving the approved pancreatic cancer chemotherapy drug
      gemcitabine directly into the pancreas in the area of the cancer and at a slow rate of
      infusion is a safe and effective treatment.

      Objectives:

      - To test the safety and effectiveness of administering gemcitabine directly to a pancreatic
      tumor at a slow rate of infusion.

      Eligibility:

      - Individuals at least 18 years of age who have been diagnosed with pancreatic cancer that is
      currently too large to be removed surgically but has not yet spread to other organs.

      Design:

        -  Participants will be screened with a full medical history and physical examination,
           blood and urine tests, and imaging studies.

        -  Participants will undergo pancreatic angiography and embolization, during which a
           catheter will be threaded into the blood vessels near the pancreas and a contrast dye
           will be used to show the blood vessels supplying the tumor. These blood vessels will
           then be surgically closed off.

        -  After the embolization, gemcitabine will be given as an infusion into the area around
           the tumor over 24 hours.

        -  Participants will return to the clinical center every 2 weeks after the first infusion
           for additional infusions of gemcitabine, using the same procedures as above.
           Participants will be monitored with frequent blood tests and imaging studies.

        -  Two weeks after the fourth treatment (course 1), participants will have more imaging
           studies, a physical examination, and blood tests. If the tumor is shrinking,
           participants will have two more courses of treatment (eight more infusions of
           gemcitabine).

        -  Participants will have followup visits every 3 months for 2 years following the last
           treatment and then every 6 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:

        -  Pancreatic cancer is the fourth leading cause of cancer death in the United States.

        -  Surgery offers the only chance at cure; however, less than 20% of patients are
           considered resectable at initial presentation.

        -  A common reason for being classified as unresectable is loco-regional advanced disease.

        -  Several phase I studies of regional administration of chemotherapy have proven safe.

        -  The main advantage of pancreatic cancer targeted arterial perfusion of Gemcitabine is
           achievement of higher local bio-available active drug levels at the tumor bed.

        -  The RECLAP trial is a phase I trial offering highly selective 24-hour intra-arterial
           administration of Gemcitabine via a subcutaneous port for patients with unresectable
           locally-advanced pancreatic cancer.

      Objectives:

      Primary Objective:

        -  To evaluate feasibility and toxicity of intra-arterial gemcitabine therapy (DLT).

        -  To establish the maximum tolerated dose (MTD)

      Secondary Objectives:

        -  To evaluate response rate using RECIST, PET, MRI and CT perfusion criteria (EASL)

        -  To determine progression free and overall survival.

        -  To evaluate the conversion rate from unresectable or borderline resectable to
           potentially resectable pancreatic cancer.

        -  To determine progression-free and overall survival.

        -  To analyze potential selection criteria to be used in future studies for patients who
           present with marginally unresectable or unresectable locally-advanced pancreatic cancer
           that might benefit from this approach.

      Eligibility:

        -  Unresectable locally-advanced pancreatic cancer.

        -  18 years old or greater with an ECOG 0-2

        -  Laboratory and physical examination parameters within acceptable limits by standard of
           practice guidelines prior to surgery or chemotherapy.

        -  No extra-pancreatic disease except regional lymph nodes.

      Design:

        -  This is a dose escalation phase-I study.

        -  Patients considered unresectable due to locally-advanced pancreatic cancer will receive
           selective arterial perfusion of gemcitabine over 24 hours via a subcutaneous indwelling
           port.

        -  Treatment will be given on Days 1 and 14. One cycle = 4 weeks for up to six cycles.

        -  Three to six patients will be enrolled per dose cohort.

        -  18 to 36 patients in 7 cohorts will be accrued plus 6 more patients at the MTD over 36
           months. Patients will be evaluated every 2 cycles (8 weeks). Upon progression patients
           will be taken off study. If no PD, patients will continue up to 6 cycles.

        -  Chemotherapy na(SqrRoot) ve patients and patients who received previously chemotherapy
           including gemcitabine will be allowed, as this mode of administration has better
           bioavailability, offer potential for better biological effect and less systemic toxicity
           profiles.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 26, 2011</start_date>
  <completion_date type="Actual">July 23, 2014</completion_date>
  <primary_completion_date type="Actual">July 23, 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate feasibility and DLT (dose limiting toxicity).</measure>
    <time_frame>three years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To establish the MTD (maximal tolerated dose)</measure>
    <time_frame>three years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Evaluate response rate using RECIST, PET, MRI and CT perfusion criteria</measure>
    <time_frame>three years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine progression-free and overall survival</measure>
    <time_frame>three years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the conversion rate from unresectable or borderline resectable to</measure>
    <time_frame>three years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To analyze potential selection criteria to be used in future studies for patients</measure>
    <time_frame>three years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Histologically or Cytologically Confirmed Pancreatic Ca</condition>
  <condition>Unresectable or Borderline Resectable Pancreatic Ca</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>gemcitabine dose escalation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

          -  Histologically or cytologically confirmed locally advanced pancreatic adenocarcinoma
             or clinical and radiographic evidence of pancreatic cancer

        Note: Patients with a limited disease burden outside the pancreas, who have undergone
        systemic chemotherapy for metastatic disease and have achieved a complete response on the
        metastatic lesions of greater than or equal to 6 months, and have no evidence of disease
        outside the pancreas at time of enrollment, are eligible.

          -  Disease must be evaluable

          -  Disease should be deemed unresectable by the MD Anderson criteria

          -  Patients may be chemo naive or have received prior chemotherapy (including
             Gemcitabine) and/or radiation

          -  Greater than or equal to 18 years of age

          -  Must be able to understand and sign the Informed Consent Document

          -  Clinical performance status of ECOG less than or equal to 2

          -  Life expectancy of greater than three months

          -  Patients of both genders must be willing to practice birth control during and for four
             months after receiving chemotherapy

          -  Hematology:

               -  Absolute neutrophil count greater than 1300/mm(3) without the support of
                  Filgrastim.

               -  Platelet count greater than 75,000/mm(3).

               -  Hemoglobin greater than 8.0 g/dl.

          -  Chemistry:

               -  Serum ALT/AST less or equal to 3 times the upper limit of normal, unless patient
                  carries a biliary stent. For these patients, to account for asymptomatic,
                  transient elevations in transaminases ('transaminitis'), serum ALT/AST may be
                  less than or equal to 5 tims the upper limit of normal provided all other
                  eligibility parameters are met.

               -  Serum creatinine less than or equal to 1.8 mg/dl unless the measured creatinine
                  clearance is greater than 60 mL/min/1.73 m(2)

               -  Total bilirubin less than or equal to 2 mg/dl,

               -  PT within 2 seconds of the upper limit of normal or INR less than or equal to 1.8

          -  No history of prior/other malignancies within the 2 years prior to enrollment with the
             exception of basal cell carcinoma

        EXCLUSION CRITERIA:

          -  Metastatic disease including malignant ascities

          -  Women of child-bearing potential who are pregnant or breastfeeding because of the
             potentially dangerous effects of the chemotherapy on the fetus or infant.

          -  Active systemic infections, coagulation disorders or other major medical illnesses of
             the cardiovascular, respiratory or immune system, myocardial infarction, heart failure

          -  Childs B or C cirrhosis or with evidence of severe portal hypertension by history,
             endoscopy, or radiologic studies

          -  Weight less than 40 kg

          -  Significant ascites, greater than 1000cc in the absence of peritoneal disease

          -  Concomitant medical problems that would place the patient at an unacceptable risk for
             the procedure

          -  Need for concurrent chemotherapy

          -  Discretion of the PI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Udo Rudloff, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rod√©s J; EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001 Sep;35(3):421-30.</citation>
    <PMID>11592607</PMID>
  </reference>
  <reference>
    <citation>Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49. doi: 10.3322/caac.20006. Epub 2009 May 27.</citation>
    <PMID>19474385</PMID>
  </reference>
  <reference>
    <citation>Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg. 1999 Jul;189(1):1-7.</citation>
    <PMID>10401733</PMID>
  </reference>
  <verification_date>August 20, 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2011</study_first_submitted>
  <study_first_submitted_qc>February 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2011</study_first_posted>
  <last_update_submitted>October 5, 2017</last_update_submitted>
  <last_update_submitted_qc>October 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2017</last_update_posted>
  <keyword>Pancreatic Cancer</keyword>
  <keyword>Regional Therapy</keyword>
  <keyword>Selective Arterial Infusion</keyword>
  <keyword>Locally Advanced Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>December 6, 2017</submitted>
    <returned>January 4, 2018</returned>
    <submitted>May 16, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

